Validation of a high-performance liquid chromatographic-radioimmunoassay method for the determination of lacidipine in plasma.
A sensitive and reproducible method for the determination of lacidipine, a new potent antihypertensive dihydropyridine, is reported. The method involves solid-phase extraction, reversed-phase high-performance liquid chromatography and radioimmunoassay of the collected fraction. The assay provides a limit of detection of 20 pg/ml of plasma, allowing the determination of trough (24 h) plasma concentrations. The method is suitable for pharmacokinetic studies in man.
Pellegatti
M
M
Research Laboratories, Glaxo S.p.A., Verona, Italy.
Braggio
S
S
Sartori
S
S
Franceschetti
F
F
Bolelli
G F
GF
D000818:Animals; D002606:Charcoal; D002851:Chromatography, High Pressure Liquid; D003911:Dextrans; D004095:Dihydropyridines / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D011817:Rabbits; D011863:Radioimmunoassay; D013056:Spectrophotometry, Ultraviolet
D003911:Dextrans; D004095:Dihydropyridines; D002606:Charcoal; C060285:lacidipine